Invesco Ltd. Chroma Dex Corp. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Chroma Dex Corp. stock. As of the latest transaction made, Invesco Ltd. holds 36,709 shares of CDXC stock, worth $201,532. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,709

Previous 89,719 59.08%

Holding current value

$201,532

Previous $244,000 45.49%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$2.51 - $3.8 $133,055 - $201,438	-53,010 Reduced 59.08%	36,709 $133,000
Q2 2024 Aug 13, 2024	BUY	$2.44 - $4.32 $218,914 - $387,586	89,719 New	89,719 $244,000
Q2 2022 Aug 15, 2022	SELL	$1.59 - $2.7 $25,104 - $42,630	-15,789 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.02 - $3.92 $787 - $1,528	-390 Reduced 2.41%	15,789 $39,000
Q4 2021 Feb 14, 2022	SELL	$3.74 - $6.7 $1,750 - $3,135	-468 Reduced 2.81%	16,179 $61,000
Q3 2021 Nov 15, 2021	BUY	$6.05 - $10.41 $24,768 - $42,618	4,094 Added 32.61%	16,647 $104,000
Q2 2021 Aug 17, 2021	SELL	$6.66 - $10.92 $5.32 Million - $8.73 Million	-799,151 Reduced 98.45%	12,553 $124,000
Q1 2021 May 17, 2021	BUY	$4.59 - $18.74 $3.73 Million - $15.2 Million	811,704 New	811,704 $7.58 Million
Q2 2019 Aug 14, 2019	SELL	$3.71 - $4.83 $249,337 - $324,609	-67,207 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.2 - $4.19 $18,016 - $23,589	5,630 Added 9.14%	67,207 $282,000
Q4 2018 Feb 14, 2019	BUY	$2.8 - $4.22 $172,415 - $259,854	61,577 New	61,577 $211,000

Others Institutions Holding CDXC

# of Institutions

Shares Held

17.2M

Call Options Held

66.7K

Put Options Held

8.2K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $375M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account